Sidoti Comments on Kamada's FY2028 Earnings (NASDAQ:KMDA)

Key Points

• Sidoti expects Kamada to earn $0.60 per share in FY2028, above the current analyst consensus estimate of $0.49.
• Kamada’s latest quarterly results exceeded expectations, with EPS of $0.16 versus the $0.11 consensus and revenue of $54.92 million compared with estimates of $50.84 million.
• Analyst sentiment remains positive: the stock has a consensus “Buy” rating and a $13.00 target price, compared with its opening price of $7.89.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Equities researchers at Sidoti issued their FY2028 earnings per share estimates for shares of Kamada in a note issued to investors on Tuesday, August 18th. Sidoti analyst J. Sidoti anticipates that the biotechnology company will earn $0.60 per share for the year. The consensus estimate for Kamada's current full-year earnings is $0.49 per share.

Other equities research analysts have also issued reports about the stock. Benchmark reiterated a "buy" rating on shares of Kamada in a research report on Tuesday, July 21st. Weiss Ratings downgraded shares of Kamada from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, June 25th. William Blair set a $15.00 target price on shares of Kamada in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of Kamada from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $13.00.

Kamada Stock Performance

Kamada stock opened at $7.89 on Thursday. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35. The firm has a market capitalization of $453.75 million, a price-to-earnings ratio of 20.76, a price-to-earnings-growth ratio of 0.64 and a beta of 0.86. The stock's fifty day moving average is $7.26 and its two-hundred day moving average is $7.94.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05. The firm had revenue of $54.92 million during the quarter, compared to analysts' expectations of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

Institutional Trading of Kamada

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC boosted its stake in shares of Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 3,862 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Kamada in the 4th quarter valued at about $66,000. XTX Topco Ltd purchased a new position in Kamada in the 4th quarter valued at about $103,000. SIH Partners LLLP purchased a new position in Kamada in the 4th quarter valued at about $134,000. Finally, Quadrature Capital Ltd lifted its holdings in Kamada by 53.5% in the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company's stock valued at $155,000 after purchasing an additional 7,627 shares in the last quarter. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Cuts Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th will be issued a $0.17 dividend. This represents a dividend yield of 219.0%. The ex-dividend date of this dividend is Thursday, August 27th. Kamada's payout ratio is 50.00%.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source